Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOLIFE SOLUTIONS INCBLFS · Entity 4614 | Chief Revenue Officer | September 16, 2024 | September 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOLIFE SOLUTIONS INC
Report date September 16, 2024 · Filed September 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 114,773 |
Reported balance
After 2024-09-16 transaction · row 1
1 source rowRow 1 · 2024-09-16 · Sale · Disposed 3,070 · Balance 114,773 F1: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 10-01-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 10-01-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2024 Filed Sep 18, 2024 21:44 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,070 | $25.12 | $77,118.40 |
DisclosureSEC source: 0001628280-24-040829 · wk-form4_1726695878.xml · nonDerivative · entry 1 Richardson Garrie · CIK 0001999183 · Chief Revenue Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,773 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 10-01-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:45 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 12,516 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-010752 · wk-form4_1710294297.xml · nonDerivative · entry 1 Richardson Garrie · CIK 0001999183 · Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,843 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2024 compensation. Read SEC document |
| October 19, 2023 Filed Nov 1, 2023 21:29 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 36,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-036051 · wk-form4_1698874172.xml · nonDerivative · entry 1 Richardson Garrie · CIK 0001999183 · Chief Revenue Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,327 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter annually, in 4 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2023 compensation in connection with their appointment as Chief Revenue Officer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.